Azitra Inc   (AZTR)
Other Ticker:  
Price: $0.1902 $-0.01 -5.888%
Day's High: $0.209 Week Perf: 0.11 %
Day's Low: $ 0.19 30 Day Perf: -13.58 %
Volume (M): 417 52 Wk High: $ 2.80
Volume (M$): $ 79 52 Wk Avg: $1.02
Open: $0.21 52 Wk Low: $0.16

 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 20
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Azitra Inc
Azitra Inc is a biotechnology company focused on developing and commercializing microbiome-based therapies to treat skin diseases and conditions. Their proprietary platform involves the use of natural, commensal bacteria to deliver therapeutic proteins to the skin. By harnessing the power of the microbiome, Azitra aims to provide safe and effective treatments for a range of conditions including eczema, acne, and rare genetic skin disorders. The company is actively conducting research and clinical trials to advance their product pipeline and bring innovative treatments to patients in need.

   Company Address: 21 Business Park Drive Branford 6405 CT
   Company Phone Number: 646-6446   Stock Exchange / Ticker: NYSEAMER AZTR
   AZTR is expected to report next financial results on August 13, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Biostax Corp

Biostax Corp announced operating deficit in the first quarter of 2024

The Major Pharmaceutical Preparations sector observers continue to analyze the first quarter of 2024 results. Presently they follow operating deficit of $-0.265327 million, from the Biostax Corp, which has not specified any revenue yet, for the respective January to March 31 2024 reporting period.

Ayala Pharmaceuticals Inc

Major Pharmaceutical Preparations company, decline in the company conduct during the most recent fiscal period

The stockholders have not anticipated some modifications at the top-line during the the October to December 31 2023 reporting season at the company. Yet, they observe ADXSs' operating deficit that was at $-8.78 million, in the same period.

Bioxytran Inc

As one of many companies, the BIXT disclosed also its first quarter of 2024 numbers

While the January to March 31 2024 reporting season continues, countless companies have announced the respective numbers. Some of them, are several constituents of the Major Pharmaceutical Preparations industry. And now, BIXT disclosed operating deficit of $-0.783791 million, for the January to March 31 2024 period.

Intercure Ltd

A sharpe Deterioration -8.524 %, in revenue at the Intercure Ltd all along the October to December 31 2023 financial period

Lower orders led to fading revenue and an increased shortfall, in the October to December 31 2023 financial period INCR posted a shortfall per stock at $-1.36 per share, while Revenue went down by -8.524 % to $355.55 million, year on year.

Pulmatrix Inc

EPS deteriorated while revenue elevated on the another level at the Pulmatrix Inc in the fiscal three months closing Mar 31 2024

Following bewildering Revenue rise of 292.595 % year on year to $5.89 million in its Mar 31 2024 report, Pulmatrix Inc s' profits turned positive at $0.23. PULMs' shines in the first quarter of 2024, as most of the businesses in the Major Pharmaceutical Preparations sectors are struggling with the Declining orders and battling with diminishing revenue.

  Company Estimates
  Revenue Outlook
Azitra Inc does not provide revenue guidance.

Earnings Outlook
Azitra Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com